1
|
Pourabdollah Toutkaboni M, Askari E, Khalili N, Tabarsi P, Jamaati H, Velayati AA, Dorudinia A, Rezaei M, Nadji SA, Mohamadnia A, Khalili N. Demographics, laboratory parameters and outcomes of 1061 patients with coronavirus disease 2019: a report from Tehran, Iran. New Microbes New Infect 2020; 38:100777. [PMID: 33042553 PMCID: PMC7534790 DOI: 10.1016/j.nmni.2020.100777] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2020] [Revised: 09/27/2020] [Accepted: 09/29/2020] [Indexed: 01/08/2023] Open
Abstract
We aimed to determine the characteristics of coronavirus disease 2019 (COVID-2019) among the Iranian population. In this study, we collected and analysed the demographics, laboratory findings and outcomes of patients with COVID-19 who were admitted to Masih Daneshvari Hospital in Tehran, Iran between 20 February 2020 and 2 April 2020. Among 1061 patients, 692 (65.2%) were male and the median age was 55 years (interquartile range (IQR), 44–66 years). Totally, 129 (12.2%) patients died during hospitalization in the ward or intensive care unit. From the remaining 932 individuals, 46 (5.0%) were admitted to the intensive care unit and 886 (95.0%) were hospitalized in the ward. Those patients who died were significantly older than those hospitalized in the ward (p < 0.001). The median absolute number of lymphocytes was 1.2 × 103/μL (IQR 0.9 × 103 to 1.6 × 103/μL) and 708 (66.7%) patients had lymphopenia (absolute lymphocyte count <1500/μL). Among the laboratory tests, D-dimer, serum ferritin and albumin had the strongest correlations with mortality (r = 0.455, r = 0.412, r = –0.406, respectively; p < 0.001 for each one). In conclusion, laboratory findings could provide useful information with regard to the management of individuals with COVID-19.
Collapse
Affiliation(s)
- M Pourabdollah Toutkaboni
- Chronic Respiratory Diseases Research Centre, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - E Askari
- Chronic Respiratory Diseases Research Centre, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - N Khalili
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.,Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
| | - P Tabarsi
- Clinical TB and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - H Jamaati
- Chronic Respiratory Diseases Research Centre, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - A A Velayati
- Mycobacteriology Research Centre (MRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - A Dorudinia
- Chronic Respiratory Diseases Research Centre, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - M Rezaei
- Virology Research Centre, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - S A Nadji
- Virology Research Centre, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - A Mohamadnia
- Chronic Respiratory Diseases Research Centre, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - N Khalili
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.,Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran
| |
Collapse
|
2
|
Mohamadnia A, Salehi Z, Namvar Z, Tabarsi P, Pourabdollah-Toutkaboni M, Rezaie S, Marjani M, Moniri A, Abtahian Z, Mahdaviani SA, Mortezaee V, Askari E, Sharifynia S. Molecular identification, phylogenetic analysis and antifungal susceptibility patterns of Aspergillusnidulans complex and Aspergillusterreus complex isolated from clinical specimens. J Mycol Med 2020; 30:101004. [PMID: 32534826 DOI: 10.1016/j.mycmed.2020.101004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2019] [Revised: 03/15/2020] [Accepted: 05/26/2020] [Indexed: 11/28/2022]
Abstract
OBJECTIVE Aspergillus sections Terrei and Nidulantes are the less common causes of invasive aspergillosis and pulmonary aspergillosis (PA) in immunocompromised patients when compared to A. fumigatus and A. flavus. Identifying these fungi as the infectious agent is crucial because of the resistance to amphotericin B (AMB) and increased lethality. The aim of this study was to identify the molecular status, evaluate the genetic diversity and examine the antifungal susceptibility profile of the uncommon Aspergillus species. Forty-five uncommon Aspergillus species were identified based on the microscopic and macroscopic criteria. Then, the molecular identification was performed using the sequencing beta tubulin (benA) gene. In vitro antifungal susceptibility to amphotericin B (AMB), itraconazole (ITC), ravuconazole (RAV), voriconazole (VRC), caspofungin (CFG) isavuconazole (ISA) and posaconazole (POS) test was performed according to the CLSI M38-A2 guidelines. RESULTS A. terreus was the most species detected, followed by A. nidulans, A. latus, A.ochraceus, and A. citrinoterreus, respectively. The analysis of the benA gene showed the presence of 12 distinct genotypes among the A. terreus isolates. The other species did not show any intraspecies variation. CFG exhibited the lowest MEC50/MIC50 (0.007μg/mL), followed by POS (0.125μg/mL), VRC, ITC, ISA (0.25μg/mL), RAV (0.5μg/mL), and AMB (8μg/mL). Among all the isolates, only 15.5% (7/45) were susceptible to AMB. CONCLUSION Antifungal susceptibility pattern of the uncommon Aspergillus species is useful to improve patient management and increase knowledge concerning the local epidemiology. Moreover, this information is necessary when an outbreak dealing with drug-resistant infections occurs.
Collapse
Affiliation(s)
- A Mohamadnia
- Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Z Salehi
- Department of Mycology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran 14115-331, Iran
| | - Z Namvar
- Department of Biotechnology, Animal Breeding Center, Tehran, Iran
| | - P Tabarsi
- Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - M Pourabdollah-Toutkaboni
- Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - S Rezaie
- Division of Molecular Biology, Department of Medical Mycology and Parasitology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| | - M Marjani
- Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - A Moniri
- Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Z Abtahian
- Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - S A Mahdaviani
- Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - V Mortezaee
- Department of Medical mycology, Mazandaran University of Medical Sciences, Sari, Iran
| | - E Askari
- Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - S Sharifynia
- Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
3
|
Nasiri M, Heidary M, Azimi T, Goudarzi H, Tabarsi P, Darban-Sarokhalil D, Feizabadi M. Mycobacterium simiae pulmonary disease in Iran: systematic review and meta-analysis. New Microbes New Infect 2018; 26:118-123. [PMID: 30370055 PMCID: PMC6199180 DOI: 10.1016/j.nmni.2018.09.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2018] [Revised: 09/11/2018] [Accepted: 09/13/2018] [Indexed: 02/05/2023] Open
Abstract
Mycobacterium simiae is one of the most common nontuberculous mycobacteria (NTM) microorganisms causing lung disease in many countries in the world. A reliable estimate of the extent of M. simiae pulmonary disease has not been well investigated in Iran. We systematically searched multiple databases to identify relative studies. Studies were excluded if they did not use the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) diagnostic criteria for NTM diseases. Data were extracted independently and in duplicate. We assessed pooled estimate by using a random model effect, and sources of heterogeneity were assessed by using Cochran's Q and the I 2 statistic. The potential for publication bias was explored by using Begg's and Egger's tests. All analyses were conducted with Stata 14.0 (StataCorp, College Station, TX, USA). Of 172 articles identified, seven met the inclusion criteria. Of 355 patients who were culture positive for NTM, 82 had M. simiae pulmonary disease according to the ATS/IDSA diagnostic criteria. The pooled frequency of M. simiae pulmonary disease among patients with NTM was 25.0% (95% confidence interval, 16.8-33.2). No evidence of publication bias was observed among the included studies (p >0.05 for Begg's and Egger's tests). Clinical isolates of M. simiae are increasingly being recognized as a cause of pulmonary disease in Iran and need further attention by health authorities.
Collapse
Affiliation(s)
- M.J. Nasiri
- Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - M. Heidary
- Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - T. Azimi
- Department of Medical Microbiology, School of Public Health, Tehran, Iran
| | - H. Goudarzi
- Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - P. Tabarsi
- Clinical TB and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - D. Darban-Sarokhalil
- Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - M.M. Feizabadi
- Department of Medical Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
4
|
Masjedi MR, Hosseini M, Aryanpur M, Mortaz E, Tabarsi P, Soori H, Emami H, Heidari G, Dizagie MK, Baikpour M. The effects of smoking on treatment outcome in patients newly diagnosed with pulmonary tuberculosis. Int J Tuberc Lung Dis 2017; 21:351-356. [DOI: 10.5588/ijtld.16.0513] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- M. R. Masjedi
- Shahid Beheshti University of Medical Sciences, Tehran
| | - M. Hosseini
- Department of Epidemiology and Biostatistics, School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran
| | - M. Aryanpur
- Tobacco Prevention and Control Research Centre, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - E. Mortaz
- Division of Pharmacology and Pathophysiology Utrecht Institute for Pharmaceutical Sciences, Faculty of Sciences, Utrecht University, Utrecht, The Netherlands
| | - P. Tabarsi
- Clinical Tuberculosis and Epidemiology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran
| | - H. Soori
- Safety Promotion and Injury Prevention Research Centre, Shahid Beheshti University of Medical Sciences, Tehran
| | - H. Emami
- Department of Epidemiology and Biostatistics, School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran
| | - G. Heidari
- Department of Epidemiology and Biostatistics, School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran
| | - M. K. Dizagie
- Mycobacteriology Research Center, Biostatistics Unit, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - M. Baikpour
- Department of Epidemiology and Biostatistics, School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran
| |
Collapse
|
5
|
Aryanpur M, Masjedi MR, Hosseini M, Mortaz E, Tabarsi P, Soori H, Emami H, Heydari G, Baikpour M. Cigarette smoking in patients newly diagnosed with pulmonary tuberculosis in Iran. Int J Tuberc Lung Dis 2017; 20:679-84. [PMID: 27084824 DOI: 10.5588/ijtld.15.0662] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The association between pulmonary tuberculosis (PTB) and tobacco smoke has been verified by most studies on the subject; figures from different countries for the prevalence of smoking among PTB patients vary. OBJECTIVE To assess the prevalence of and factors associated with smoking among TB patients in Iran. DESIGN In this cross-sectional study, subjects were included on a first-come, first-served basis from among newly diagnosed PTB patients using a multistage cluster sampling method during 2012-2014. Data were collected during face-to-face interviews and a questionnaire was used to gather information on smoking habits. RESULTS Of 1127 newly diagnosed PTB patients included in the study (mean age 50.0 ± 19.8 years), 228 (20.2%) were daily smokers, 20 (1.8%) were occasional smokers and 93 (8.9%) had quit before diagnosis. Simultaneous drug use (P < 0.001, OR 75.21), increasing age (P = 0.001), being single (P < 0.001, OR 16.95), being an Iranian national (P < 0.001, OR 6.26) and living in a rural area (P < 0.001, OR 5.85) were found to be independent risk factors for smoking in study patients. CONCLUSION The prevalence of smoking among PTB patients in Iran is relatively high. It is therefore necessary to include smoking cessation interventions in the National TB Programme.
Collapse
Affiliation(s)
- M Aryanpur
- Tobacco Prevention and Control Research Centre, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - M R Masjedi
- Clinical Tuberculosis and Epidemiology Research Center, NRITLD, Department of Internal Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - M Hosseini
- Department of Epidemiology and Biostatistics, School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran
| | - E Mortaz
- Department of Immunology, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Division of Pharmacology and Pathophysiology Utrecht Institute for Pharmaceutical Sciences, Faculty of Sciences, Utrecht University, Utrecht, The Netherlands
| | - P Tabarsi
- Clinical Tuberculosis and Epidemiology Research Center, NRITLD, Department of Internal Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - H Soori
- Safety Promotion and Injury Prevention Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - H Emami
- Tobacco Prevention and Control Research Centre, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - G Heydari
- Tobacco Prevention and Control Research Centre, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - M Baikpour
- Department of Epidemiology and Biostatistics, School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
6
|
Baghaei P, Marjani M, Tabarsi P, Moniri A, Rashidfarrokhi F, Ahmadi F, Nassiri AA, Masjedi MR, Velayati AA, Cattamanchi A. Impact of chronic renal failure on anti-tuberculosis treatment outcomes. Int J Tuberc Lung Dis 2014; 18:352-6. [DOI: 10.5588/ijtld.13.0726] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
7
|
Fahimi F, Tabarsi P, Kobarfard F, Bozorg BD, Goodarzi A, Dastan F, Shahsavari N, Emami S, Habibi M, Salamzadeh J. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 2013; 17:1602-6. [DOI: 10.5588/ijtld.13.0019] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
8
|
Marjani M, Baghaei P, Tabarsi P, Shamaei M, Mansouri D, Masjedi MR, Velayati A. Drug resistance pattern and outcome of treatment in recurrent episodes of tuberculosis. East Mediterr Health J 2012; 18:957-61. [PMID: 23057389 DOI: 10.26719/2012.18.9.957] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Patterns of drug resistance in recurrent cases of tuberculosis may be different than in those without a history of treatment. In this retrospective study, the drug resistance pattern and outcome of treatment with DOTS category I (CAT I) regimen was compared in 63 recurrent cases and 872 new cases of pulmonary tuberculosis from April 2003 to January 2008 at the National Research Institute of Tuberculosis and Lung Disease in Tehran, Islamic Republic of Iran. Resistance to isoniazid and ethambutol was significantly more common in recurrent cases, but there were no differences in rates of resistance to rifampin, pyrazinamide, streptomycin or the rate of multi-drug resistant strains. Resistance to streptomycin was the most common. No significant differences in treatment outcome and deaths were found between the 2 groups. Due to the low frequency of multi-drug resistance in the recurrent cases, a CAT I regimen may be suitable for empirical therapy before drug sensitivity results become available.
Collapse
Affiliation(s)
- M Marjani
- Clinical Tuberculosis and Epidemiology Research Centre, National Research Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran.
| | | | | | | | | | | | | |
Collapse
|
9
|
Tabarsi P, Chitsaz E, Moradi A, Baghaei P, Farnia P, Marjani M, Shamai M, Amiri M, Nikaein S, Mansouri D, Masjedi M, Altice F. Treatment outcome, mortality and their predictors among HIV-associated tuberculosis patients. Int J STD AIDS 2012; 23:e1-4. [PMID: 23033530 PMCID: PMC3495268 DOI: 10.1258/ijsa.2009.009093] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The risk of death is significantly higher in HIV-infected patients with tuberculosis (TB). This study aims to evaluate the impact of demographic, clinical and laboratory characteristics on the treatment outcome and mortality of TB/HIV co-infected patients in a tertiary TB centre in Iran. In total, 111 patients were recruited from 2004 to 2007. Mycobacteriological studies and demographic, clinical, and laboratory data from all patients were analysed and predictors of unsuccessful outcomes as well as mortality were determined. The mean age for all 111 TB-HIV patients was 38 ± 9 years (range 22-70) and 107 (96.3%) were men; 104 (93.7%) had a history of drug abuse and 96 (86.4%) had a history of imprisonment. The method of HIV transmission was intravenous drug use in 88 (79.3%). Twenty-three (20.7%) had a history of Category 1 (CAT I) TB treatment and six (5.4%) Category 2 (CAT II) treatment. Combination antiretroviral therapy (cART) was given to 48 (43.2%). No significant associations were found between treatment outcomes or mortality and gender, smoking, drug and alcohol abuse, imprisonment, method of transmission, history of CAT I and CAT II treatments, CD4 counts or adverse effects (P > 0.05). Administration of cART led to significantly better outcomes (P < 0.001). Lower serum albumin levels and low body weight were significantly associated with mortality.
Collapse
Affiliation(s)
- P Tabarsi
- Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Tabarsi P, Moradi A, Baghaei P, Marjani M, Shamaei M, Mansouri N, Chitsaz E, Farnia P, Mansouri D, Masjedi M, Velayati A. Standardised second-line treatment of multidrug-resistant tuberculosis during pregnancy. Int J Tuberc Lung Dis 2011; 15:547-50. [PMID: 21396217 DOI: 10.5588/ijtld.10.0140] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
We describe the efficacy and outcome of standardised second-line anti-tuberculosis (TB) medications during pregnancy. Treatment outcomes of five pregnant women with documented multidrug-resistant TB (MDR-TB) referred to the National Research Institute of Tuberculosis and Lung Diseases from 2003 to 2009 were analysed in two categories, maternal and neonatal. Patients became pregnant during treatment for MDR-TB without any changes in their anti-tuberculosis regimen. None of them had any adverse effects during pregnancy and delivery. No adverse effects were observed in mothers or neonates. The treatment of MDR-TB during pregnancy with a standardised second-line regimen in this study population was safe, with an acceptable rate of treatment success.
Collapse
Affiliation(s)
- P Tabarsi
- Mycobacteriology Research Centre, National Research Institute of Tuberculosis and Lung Diseases, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Velayati AA, Farnia P, Merza MA, Zhavnerko GK, Tabarsi P, Titov LP, Ghanavei J, Farnia P, Setare M, Poleschuyk NN, Owlia P, Sheikolslami M, Ranjbar R, Masjedi MR. New insight into extremely drug-resistant tuberculosis: using atomic force microscopy. Eur Respir J 2011; 36:1490-3. [PMID: 21119210 DOI: 10.1183/09031936.00064510] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
12
|
Shamaei M, Marjani M, Farnia P, Tabarsi P, Mansouri D. Human infections due to Mycobacterium lentiflavum: first report in Iran. Iran J Microbiol 2010; 2:27-9. [PMID: 22347547 PMCID: PMC3279769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Non-tuberculosis mycobacteria (NTM), as certain species of mycobacteria, can affect human in several ways. In the preceding years, the rate of NTM detection has risen in both immunocompromised and immunocompetent patients. On the other hand, several reports have debated the possibility of co-infection of both Mycobcateriu tuberculosis (MTB) and NTM in individuals that puts the role of NTM in disease manifestations under question. Moreover, it is now proven that some of the cases that are identified as anti-TB treatment failure or suspected for drug resistance are actually NTM.
Collapse
Affiliation(s)
- M Shamaei
- Clinical Tuberculosis and Epidemiology Research Center,Corresponding author: Masoud Shamaei. Address: Masih Daneshvari Hospital, Darabad, Niavaran Sq, Tehran, Iran. Tel:+98-21-26102036. Fax:+98-21-26109590.
| | - M Marjani
- Clinical Tuberculosis and Epidemiology Research Center
| | - P Farnia
- Mycobacteriology Research Center
| | | | - D Mansouri
- Clinical Tuberculosis and Epidemiology Research Center,Chronic Respiratory Disease Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical.Sciences, Tehran, Iran
| |
Collapse
|
13
|
Shadmehr MB, Arab M, Pejhan S, Daneshvar A, Javaherzadeh N, Abbasi A, Ahmadi ZH, Radpay B, Dabir S, Parsa T, Mohammadi F, Mansoori SD, Tabarsi P, Amiri MV, Marjani M, Kashani BS, Najafizadeh K, Shafaghi S, Ghorbani F, Masjedi MR, Velayati AA. Eight years of lung transplantation: experience of the National Research Institute of Tuberculosis and Lung Diseases. Transplant Proc 2010; 41:2887-9. [PMID: 19765464 DOI: 10.1016/j.transproceed.2009.07.016] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
BACKGROUND Lung transplantation has evolved from an experimental procedure to a viable therapeutic option in many countries. In Iran, the first single-lung transplantation was performed in the year 2000, more than 3 decades after the first successful procedure in the world, and the first double-lung transplantation was performed in the year 2006. OBJECTIVE To describe our 8-year experience in lung transplantation. PATIENTS AND METHODS During 8 years, we performed 24 lung transplantation procedures. Underlying lung diseases were pulmonary fibrosis in 16 patients (66.6%); chronic obstructive pulmonary disease in 2 (8.3%); bronchiectasis in 5, including 2 patients with cystic fibrosis (20.8%), and alveolar microlithiasis in 1 (4.16%). Data for all patients were collected and analyzed. Procedures were carried out using standardized methods. The induction suppression regimen consisted of cyclosporine and methylprednisolone. Maintenance immunosuppression drugs were cyclosporine and mycophenolate mofetil, and tapering dosage of prednisolone. Patients were followed up with physical examinations, 3 times a week, as well as and cycle ergometry 3 times a week and spirometry and laboratory tests once a week and chest radiography per needed for up to 3 months posttransplantation. RESULTS The longest survival time was 7.2 years, in a 60-year-old patient with idiopathic pulmonary fibrosis. Fourteen patients died, 8 as a result of hemodynamic instability and/or hemorrhage, 1 as a result of bone and fat emboli, 3 after cessation of drug and 2 of them after infection. CONCLUSION Although lung transplantation is a complex procedure it can be performed in developing countries such as Iran.
Collapse
Affiliation(s)
- M B Shadmehr
- National Research Institute of Tuberculosis and Lung Diseases, Massih Daneshvari Hospital, Tehran, Iran
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Sharif-Kashani B, Ahmadi ZH, Bikdeli B, Tabarsi P, Dorudinia A, Shahabi P, Raeissi S, Shadafza B, Estahbanati G, Naji A, Saliminejad L, Bakhshayesh-Karam M, Karimi S, Khodadad K, Masjedi MR, Gavazzi A. Bilateral diffuse pulmonary infiltration in a heart transplant recipient. Transpl Infect Dis 2009; 12:258-60. [PMID: 20015115 DOI: 10.1111/j.1399-3062.2009.00483.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Pulmonary complications are not infrequent after heart transplantation. Kaposi sarcoma is a vascular tumor that can involve the skin as well as visceral organs. We describe a case of visceral and cutaneous Kaposi sarcoma that presented with diffuse bilateral pulmonary infiltration and breathlessness 6 month after heart transplantation. Following modulation of the immunosuppressive regimen and addition of chemotherapy, the patient had an excellent response and has had an uneventful 1-year follow-up.
Collapse
Affiliation(s)
- B Sharif-Kashani
- Cardiovascular Department, Masih Daneshvari Hospital, Shahid Beheshti University MC, Tehran, Iran
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Tabarsi P, Baghaei P, Hemmati N, Mirsaeidi M, Kazempour M, Mansouri D, Masjedi MR. Comparison of the effectiveness of 2 treatment regimens in patients with isoniazid-resistant tuberculosis. East Mediterr Health J 2009; 15:1346-1350. [PMID: 20218123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
We compared the effectiveness of 2 treatment regimens for isoniazid-resistant tuberculosis (TB) in 42 patients attending a TB referral centre in the Islamic Republic of Iran. The patients were divided into 2 treatment groups: 26 received the 6-month standard HRZE treatment and 16 received a modified treatment of RZE for 6 months. There were no significant differences in age or sex of the groups. With the standard method of treatment, 21 (80.8%) patients were cured, 4 (15.4%) resulted in treatment failure, and 1 (3.8%) died. In the modified treatment group, 16 (100%) patients were cured, These differences were not statistically significantly different (P = 0.194).
Collapse
Affiliation(s)
- P Tabarsi
- Mycobacteriology Research Centre, National Research Institute of Tuberculosis and Lung Disease, Shaheed Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran.
| | | | | | | | | | | | | |
Collapse
|
16
|
Velayati AA, Farnia P, Masjedi MR, Ibrahim TA, Tabarsi P, Haroun RZ, Kuan HO, Ghanavi J, Farnia P, Varahram M. Totally drug-resistant tuberculosis strains: evidence of adaptation at the cellular level. Eur Respir J 2009; 34:1202-3. [DOI: 10.1183/09031936.00081909] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
17
|
Tabarsi P, Chitsaz E, Moradi A, Baghaei P, Farnia P, Marjani M, Irannejad P, Mansouri D, Masjedi M. First-line antituberculosis drug resistance prevalence and its pattern among HIV-infected patients in the national referral tuberculosis centre, Iran. Int J STD AIDS 2009; 20:566-70. [DOI: 10.1258/ijsa.2008.008379] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The objective of this study was to determine the drug resistance prevalence and its pattern among tuberculosis (TB)–HIV patients in Iran. In this retrospective study, all admitted TB/HIV patients presenting to our tertiary centre during 2005–2007 were considered. After confirmation for TB–HIV, first-line DST was performed for culture-positive patients. The drug resistance patterns and the treatment outcomes were analysed. Of the total 92 TB/HIV patients, 27 were culture negative, and DST were available in 65. Intravenous drug abuse was seen in 59 (90.8%). Thirty-seven (57%) were ‘sensitive’ cases and 28 (43%) were ‘any drug resistance’ cases. Twenty-one (32.3%) were mono-drug, three (4.6%) poly-drug and four (6.1%) were multidrug-resistant TB patients. Previous anti-TB medication was significantly associated with any drug resistance ( P = 0.041; 95% confidence interval =0.086–0.984); however, having any drug resistance did not affect the treatment outcome ( P = 0.56). Streptomycin showed the highest resistance rate (27%) followed by isoniazid (20%), pyrazinamide (9.8%), rifampin (9.2%) and ethambutol (3%). Drug resistance to antitubercular agents in TB–HIV co-infected patients in Iran is high compared with other reports. Drug resistance is higher among those who have had prior anti-TB medication.
Collapse
Affiliation(s)
- P Tabarsi
- Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - E Chitsaz
- Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - A Moradi
- Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - P Baghaei
- Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - P Farnia
- Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - M Marjani
- Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - P Irannejad
- Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - D Mansouri
- Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - M Masjedi
- Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| |
Collapse
|
18
|
Shamaei M, Marjani M, Baghaei P, Chitsaz E, Rezaei Tabar E, Abrishami Z, Tabarsi P, Mansouri D, Masjedi MR. Drug abuse profile - patient delay, diagnosis delay and drug resistance pattern - among addict patients with tuberculosis. Int J STD AIDS 2009; 20:320-3. [PMID: 19386968 DOI: 10.1258/ijsa.2008.008299] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Socioeconomic problems limit the access of drug users to health-care services. This descriptive cross-sectional study was carried out by making use of the medical records of new case tuberculosis (TB) patients hospitalized at Masih Daneshvari Hospital, the national referral centre in Iran, from 2003 to 2006. Demographic and personal characteristics of the patients and type of disease were collected and categorized. Of the 944 patients with confirmed TB, 143 (15.1%) were drug users, among whom 140 (97.9%) were men with just three women drug users. The mean age of the drug users group was 43.04 +/- 13.81 years. The type of drug used was opium in 100 cases (69.9%), heroin in 29 (20.3%), opium and heroin together in four (2.8%) and all three, opium, heroin and crack, in two (1.4%). For 238 high-risk patients, an HIV test was performed and HIV infection was confirmed in 33 cases. Patient delay was longer in drug users (P = 0.000) against other patients, whereas diagnosis delay was shorter (P = 0.007). Drug susceptibility tests were performed for 515 patients with positive cultures. One hundred and thirty-three (14.1%) were found to have 'any resistance' to anti-TB drugs, and 10 (1.1%) individuals had multidrug-resistant TB. Twenty-six (19.5%) of the individuals who showed resistance to first-line agents were drug users. There was no significant relation between drug resistance and drug use (P = 0.4). In conclusion, it seems that active case finding for TB and HIV in addict cases must be contained in harm reduction packages. Moreover, the manifestations of the disease should be considered seriously regardless of attributing them to drug use.
Collapse
Affiliation(s)
- M Shamaei
- Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease, Masih Daneshvari University Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Mardani M, Tabarsi P, hadavand F, Taheri M, Chitsaz E, Gachkar L, Masjedi M. Accuracy of QuantiFERON-TB Gold Test Vs Tuberculin Skin Test to Detect Latent Tuberculosis Infection in HIV Positive Individuals in Iran. Int J Infect Dis 2008. [DOI: 10.1016/j.ijid.2008.05.864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
20
|
Tabarsi P, Mirsaeidi M, Amiri M, Karimi S, Masjedi MR, Mansouri D. Inappropriate use of steroid and pneumocystis jiroveci pneumonia: report of two cases. East Mediterr Health J 2008; 14:1217-1221. [PMID: 19161096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Affiliation(s)
- P Tabarsi
- National Research Institute of TB and Lung Disease, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran.
| | | | | | | | | | | |
Collapse
|
21
|
Masjedi MR, Tabarsi P, Chitsaz E, Baghaei P, Mirsaeidi M, Amiri MV, Farnia P, Javanmard P, Mansouri D, Velayati AA. Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002-2006. Int J Tuberc Lung Dis 2008; 12:750-755. [PMID: 18544199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
Abstract
BACKGROUND Multidrug-resistant tuberculosis (MDR-TB) imposes a formidable burden on national health systems. There is still no consensus on the subject, with controversies regarding treatment protocols, treatment outcomes and the various treatment regimens. METHODS The present study describes Iran's second national cohort for treatment of MDR-TB. The study comprised all documented MDR-TB cases in Iran referred to our centre during the period 2002-2006. All patients received a standardised second-line regimen consisting of ofloxacin, cycloserine, prothionamide and amikacin. Based on drug susceptibility testing results, ethambutol and pyrazinamide were added to the regimen. RESULTS Forty-three patients diagnosed with MDR-TB, with a mean age of 44.38 +/- 19.05 years, received treatment; of these, 27 (62.8%) were male. Twenty-three were (53.5%) Iranians and the remainder were Afghans. All patients were acquired MDR-TB cases. Of the 43 cases, 25 (58.1%) experienced severe clinically significant adverse effects; 29 (67.5%) had a successful outcome and 14 (32.5%) had a poor outcome (treatment failure in six [14%] and death in eight [18.6%]). Mortality was higher in Iranians (P = 0.039) and in patients whose initial regimen was changed due to adverse drug reactions (P = 0.01). CONCLUSION Compared with previous studies, our study was able to obtain more favourable outcomes of MDR-TB treatment using a standardised regimen.
Collapse
Affiliation(s)
- M R Masjedi
- Mycobacteriology Research Centre, National Research Institute of Tuberculosis and Lung Disease, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Tabarsi P, Mirsaeidi SM, Amiri M, Mansouri SD, Masjedi MR, Velayati AA. Clinical and laboratory profile of patients with tuberculosis/HIV coinfection at a national referral centre: a case series. East Mediterr Health J 2008; 14:283-291. [PMID: 18561719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
This case series describes the clinical and laboratory profile of 15 patients with tuberculosis (TB) HIV coinfection admitted to a referral centre in the Islamic Republic of Iran. Most of the patients (13) were male; the mean age was 36.9 years. Intravenous drug use was the route of transmission for all males and heterosexual intercourse for the 2 females; 12 patients had a history of imprisonment. All patients had pulmonary TB; 13 were smear-positive and all except 1 had atypical radiological presentation. Drug-induced hepatitis occurred in 3 patients and 12 had hepatitis C coinfection. Five patients died. The mean CD4 count was 229.2 (SD 199.5) cells/mm3 and 78.6% had CD4 count < 350. TB may be an AIDS-defining illness in this country.
Collapse
Affiliation(s)
- P Tabarsi
- National Research Institute of Tuberculosis and Lung Disease, Tehran, Islamic Republic of Iran.
| | | | | | | | | | | |
Collapse
|
23
|
Mackowiak PA, Heidarnejad H, Tabarsi P, Mohammadi F, Heidarzadeh N, Sajadi MM, Mansouri D. Acute Necrotizing Pneumonia in a Previously Healthy Young Adult. Clin Infect Dis 2008. [DOI: 10.1086/524735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
24
|
Mirsaeidi SM, Tabarsi P, Mardanloo A, Ebrahimi G, Amiri M, Farnia P, Sheikhleslami M, Bakayev V, Mohammadi F, Mansouri SD, Masjedi MR, Velayati AA. Pulmonary mycobacterium Simiae infection and HTLV1 infection: an incidental co-infection or a predisposing factor? Monaldi Arch Chest Dis 2008; 65:106-9. [PMID: 16913582 DOI: 10.4081/monaldi.2006.573] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
There is little information on atypical mycobacterium and human T lymphotropic virus Type I (HTLV-I) co-infection. We present the first case of pulmonary M. simiae infection in co-infection with HTLV-1, confirmed by ELISA antibody test and Western Blot. We discuss the clinical characteristics and laboratory tests of the patient and presumptive immunological relation. We propose that in patients with the HTLV infection and pulmonary symptoms and signs compatible with tuberculosis, evaluation for atypical mycobacteriosis may be recommendable.
Collapse
Affiliation(s)
- S M Mirsaeidi
- National Research Institute of Tuberculosis and Lung Disease, Shaheed Beheshti university of medical science, Tehran, Iran.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Tabarsi P, Baghaei P, Mirsaeidi M, Amiri M, Mansouri D, Novin A, Zendedel SM, Masjedi MR. Multi-drug resistant tuberculosis in pregnancy: need for more intensive treatment. Infection 2007; 35:477-8. [PMID: 17906837 DOI: 10.1007/s15010-007-6318-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2006] [Accepted: 05/24/2007] [Indexed: 10/22/2022]
Affiliation(s)
- P Tabarsi
- Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease, Shaheed Beheshti University of Medical Sciences, Tehran, Iran.
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Tabarsi P, Baghaei P, Amiri M, Emami H, Mansouri D, Masjedi M. P1618 Treatment outcome of tuberculosis patients diagnosed with human immunodeficiency virus infection in Iran. Int J Antimicrob Agents 2007. [DOI: 10.1016/s0924-8579(07)71457-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
27
|
Tabarsi P, Mansouri D, Edrissian O, Alaei A, Amiri M, Mirsaeidi SM. Perianal tuberculosis in an HIV-positive patient. East Mediterr Health J 2006; 12:923-6. [PMID: 17333842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Affiliation(s)
- P Tabarsi
- Department of Tuberculosis and HIV/AIDS, National Research Institute of Tuberculosis and Lung Diseases, Tehran, Islamic Republic of Iran
| | | | | | | | | | | |
Collapse
|
28
|
Mirsaeidi SM, Houshmand M, Tabarsi P, Banoei MM, Zargari L, Amiri M, Mansouri SD, Sanati MH, Masjedi MR. Lack of association between interferon-gamma receptor-1 polymorphism and pulmonary TB in Iranian population sample. J Infect 2006; 52:374-7. [PMID: 16233916 DOI: 10.1016/j.jinf.2005.08.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2004] [Accepted: 08/10/2005] [Indexed: 11/20/2022]
Abstract
BACKGROUND Tuberculosis is one of the most common infectious diseases in the world. In recent years, genetically approach has been developed. One of the interesting gene for investigator is IFN-gammaR1. AIM Determination of susceptibility to tuberculosis with polymorphism of IFN-gammaR1 gene. MATERIAL AND METHOD Study was prospective case-control. Fifty patients with smear positive tuberculosis have been chosen randomly. They were matched with 54 healthy controls with no history of TB. Polymorphism at 395 codon of IFN-gammaR1 gene was detected with Newport method. Data were analysed with SPSS version 11. RESULTS Mean age of patients and control were 55+/-20 and 53+/-13.5 years, respectively. Demographic characteristic had no difference within two groups. One patient in case group had heterozygote mutation at IFN-gammaR1 gene. In control group there were no mutations. CONCLUSION Genetically susceptibility to TB is not in 395 colon of IFN-gammaR1 in Iranian TB sample and polymorphism of this loci has occur in 2% of TB patients and 0.96% of total study population.
Collapse
Affiliation(s)
- S M Mirsaeidi
- National Research Institute of Tuberculosis and Lung Disease, Tehran, Iran.
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Mirsaeidi SM, Tabarsi P, Edrissian MO, Amiri M, Farnia P, Mansouri SD, Masjedi MR, Velayati AA. Primary multi-drug resistant tuberculosis presented as lymphadenitis in a patient without HIV infection. Monaldi Arch Chest Dis 2004; 61:244-7. [PMID: 15909617 DOI: 10.4081/monaldi.2004.690] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Primary multi-drug resistant extrapulmonary tuberculosis is an uncommon form of the disease, but it seems that by increasing the number drug resistant tuberculosis around the world, the number of cases of primary multidrug resistant tuberculosis with extrapulmonary presentation also is going to rise. In this report, we describe a 19- year old, HIV negative man with primary multi-drug resistant TB lymphadenitis, presented with cervical lymphadenopathy and sinus discharge at the site of involved lymph nodes. The Acid Fast Bacilli (AFB) smear of sputum was negative but the AFB smear of discharged fluid as well as the excisional biopsy of the lymph nodes confirmed the M. tuberculosis infection. The patient underwent the treatment with a combination of isoniazide, clofazimine, pyrazinamide, ofloxacin and amikacin with promising results. By increasing the number of drug resistant tuberculosis patients around the world, appropriate diagnosis and treatment of different presentations of the disease need a special attention.
Collapse
MESH Headings
- Adult
- Antitubercular Agents/therapeutic use
- Biopsy
- Diagnosis, Differential
- Drug Therapy, Combination
- Follow-Up Studies
- HIV Antibodies/analysis
- HIV Infections/diagnosis
- Humans
- Male
- Radiography, Thoracic
- Recurrence
- Tomography, X-Ray Computed
- Tuberculosis, Lymph Node/diagnosis
- Tuberculosis, Lymph Node/drug therapy
- Tuberculosis, Lymph Node/microbiology
- Tuberculosis, Multidrug-Resistant/diagnosis
- Tuberculosis, Multidrug-Resistant/drug therapy
- Tuberculosis, Multidrug-Resistant/microbiology
Collapse
Affiliation(s)
- S M Mirsaeidi
- National Research Institute of Tuberculosis and Lung Diseases, Shaheed Beheshti University of Medical Sciences, Tehran, Iran.
| | | | | | | | | | | | | | | |
Collapse
|